Purpose: Several studies show that prostate specific antigen inversely correlates with body mass index. Hemodilution may be responsible for the lower prostate specific antigen in obese men. Hematocrit is the most popular indicator of plasma volume. We examined the effect of hematocrit changes on prostate specific antigen in healthy men during 2 years. We also investigated the association between prostate specific antigen and plasma volume changes based on combined changes in body weight and hematocrit.
Materials And Methods: We reviewed the records of 8,338 men who visited our institution for routine health assessments in 2005, 2006 and 2007. Using the combination of body weight and hematocrit changes in 1 year we defined hemodilution as weight gain with decreased hematocrit and hemoconcentration as weight loss with increased hematocrit.
Results: On multiple regression analysis controlling for patient age and weight change the hematocrit change was significantly associated positively with the prostate specific antigen change between 2005 and 2006 (1.2%/1 U), and between 2006 and 2007 (0.7%/1 U, each p <0.001). After controlling for age participants with hemoconcentration showed significantly greater prostate specific antigen changes than those with hemodilution, that is 6.1% between 2005 and 2006, and 4.8% between 2006 and 2007 (each p <0.001).
Conclusions: Hematocrit change was positively associated with prostate specific antigen change. Compared to men with hemodilution significantly greater prostate specific antigen changes were observed in men with hemoconcentration. Thus, plasma volume may explain the inverse relationship between body mass index and prostate specific antigen.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.juro.2009.12.019 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Preliminary evaluation of a novel PSMA-targeting radiopharmaceutical [Ga]Ga/[Lu]Lu-NYM032 for theranostic use in prostate cancer.
Eur J Nucl Med Mol Imaging
January 2025
Department of Nuclear Medicine, Affiliated Hospital of Jiangnan University, No. 1000, Hefeng Road, Wuxi, Jiangsu Province, 214000, China.
Purpose: A novel theranostic radiopharmaceutical targeting prostate-specific membrane antigen (PSMA), [Ga]Ga/[Lu]Lu-NYM032, was developed and its diagnostic and therapeutic potential in the treatment of prostate cancer (PCa) was preliminarily evaluated.
Methods: The diagnostic efficacy of the PET tracer [Ga]Ga-NYM032 was first evaluated in PSMA-positive xenograft-bearing models (LNCaP models), followed by evaluation in 10 PCa patients using [Ga]Ga-PSMA617 a comparator. Finally, the therapeutic potential of [Lu]Lu-NYM032 was evaluated in LNCaP models.
Early experience of prostate artery embolization: a retrospective single-centre study.
Scand J Urol
January 2025
Center for Clinical Research Västmanland, Uppsala University, Sweden; Division of Surgery, Danderyd University Hospital, Stockholm, Sweden.
Objective: The aim of this study was to evaluate the early experiences of prostate artery embolization (PAE) in patients with benign prostatic hyperplasia (BPH).
Material And Methods: This retrospective study included all patients treated for BPH who were referred to the radiology department for PAE in Västmanland between 2018 and 2021. Data were collected on patient demographics, International Prostate Symptom Score (IPSS), prostate-specific antigen level, and peri- and post-procedure outcomes.
Prostate Cancer Patients' Perceptions Regarding the Relevance of a Digital Rectal Examination During Their Follow-Up After Radiation Therapy.
Cancer Med
January 2025
College of Health Sciences, University of Bordeaux, Bordeaux, France.
Background: Prostate cancer is an example of the undervaluation of clinical examinations in care of patients. After external radiotherapy, cancer recurrence is primarily determined biologically by measuring prostate-specific antigen concentration. Consequently, there is no systematic requirement for the digital rectal examination (DRE).
View Article and Find Full Text PDFAssociation of Vitamin D and Prostate Health Status in Men: An Analytical Cross-Sectional Study.
Cureus
December 2024
General Medicine, Sri Ramaswamy Memorial Medical College Hospital and Research Centre, Sri Ramaswamy Memorial Institute of Science and Technology, Kattankulathur, IND.
Introduction: Benign prostatic hyperplasia (BPH) is the most common form of lower urinary tract symptoms (LUTS). Vitamin D may be an effective way to treat BPH symptoms because it has anti-proliferative and anti-inflammatory characteristics. Thus, adequate vitamin D levels are vital for overall health.
View Article and Find Full Text PDFObjectives: We aim to determine the prognostic significance of DNA methylation () in two independent prostate cancer cohorts with long-term clinical follow-up data.
Subjects/patients And Methods: We first re-examined a published, in-house whole genome bisulphite sequencing (WGBS) prostate cancer dataset, derived from radical prostatectomy (RP) tissue ( = 15) with median follow-up 19.5 years, to confirm and visualise the association between and patient mortality.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!